Belatacept, a T cell costimulation blocker, demonstrated superior renal function, lower cardiovascular risk, and improved graft and patient survival in renal transplant recipients. Despite the potential benefits, adoption of belatacept has been limited in part due to concerns regarding higher rates and grades of acute rejection in clinical trials. Since July 2011, we have utilized belatacept-based immunosuppression regimens in clinical practice. In this retrospective analysis of 745 patients undergoing renal transplantation at our center, we compared patients treated with belatacept (n = 535) with a historical cohort receiving a tacrolimus-based protocol (n = 205). Patient and graft survival were equivalent for all groups. An increased rate of acute rejection was observed in an initial cohort treated with a protocol similar to the low-intensity regimen from the BENE-FIT trial versus the historical tacrolimus group (50.5% vs. 20.5%). The addition of a transient course of tacrolimus reduced rejection rates to acceptable levels (16%). Treatment with belatacept was associated with superior estimated GFR (belatacept 63.8 mL/min vs. tacrolimus 46.2 mL/min at 4 years, p < 0.0001). There were no differences in serious infections including rates of cytomegalovirus or BK viremia. We describe the development of a costimulatory blockade-based strategy that ultimately allows renal transplant recipients to achieve calcineurin inhibitor-free immunosuppression.
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Introduction
Kidney transplantation improves the length and quality of life in patients with end-stage renal disease (1, 2) . Increasingly effective immunosuppressive regimens have resulted in significant improvements in short-term results over the past 30 years. Unfortunately, late outcomes remain less than optimal with the majority of kidneys eventually failing and many patients returning to dialysis within 10 years (3) (4) (5) . Several mechanisms significantly contribute to late allograft loss including medication nonadherence, the development of donor-specific antibodies, chronic injury due to calcineurin inhibitor (CNI) toxicity, and recurrent disease (6, 7) . In addition to nephrotoxicity, current immunosuppressants are known to predispose patients to higher rates of diabetes, hypertension, and hyperlipidemia, contributing to accelerated rates cardiovascular disease and higher overall mortality compared with the general population (8, 9) .
Belatacept, a high-affinity derivative of the receptor fusion protein cytotoxic T lymphocyte associated protein 4-immunoglobulin, blocks signaling through CD28 by binding to its ligands CD80 and CD86, thereby inhibiting T cell activation and effector function without many of the detrimental side effects seen with conventional immunosuppression (10) . A large multicenter randomized phase III trial, the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppresion Trial (BENEFIT), evaluated the efficacy and safety of belatacept compared with cyclosporine in renal transplant recipients (11) . Belatacept treatment was associated with significantly better renal function as well as an improved metabolic profile, presumably translating into decreased cardiovascular risk (12) . Outcomes at 7 years confirmed sustained improvement in renal function in belatacepttreated patients as well as 43% risk reduction for the combined end point of graft loss and death (13) . Interestingly, belatacept treatment was associated with higher rates and grades of early rejection. Despite the observed benefits of superior renal function, reduced cardiovascular risk, and increased survival, a combination of logistical considerations and concerns about increased rates of rejection may limit widespread adoption of belatacept as a primary therapy.
As with most clinical trials, the BENEFIT trial was limited by exclusion criteria that remove certain patient populations from consideration, some of whom significantly contribute to the general recipient pool. Those with higher immunologic risk, such as retransplants or high panel reactive antibody levels, as well as those from more ethnically diverse populations were underrepresented in the trial. In addition, the immunosuppressive regimen utilized in the trial >10 years ago may not reflect currently used immunosuppressive regimens, namely, cyclosporine instead of tacrolimus in the control group as well as nonprescribed steroid treatment, which resulted in increased dosage and duration of the steroid taper compared with currently utilized regimens in which minimization is routine. This seems to be supported by the results of the BENEFIT trial, in which the cyclosporine control arm had a notably low rejection rate in the first year (%7%) (11) . It is important to evaluate and report the outcomes of belatacept-based regimens in clinical practice.
The purpose of this report was to detail our experience in the iterative development of a belatacept-based standard-of-care immunosuppressive regimen among a large, diverse cohort of renal transplant recipients and to describe the effectiveness of belatacept-versus tacrolimus-based regimens for renal function, incidence of acute rejection, infection, donor-specific antibody development, graft failure, and mortality.
Materials and Methods

Patient population
We retrospectively reviewed the outcomes of 745 adult renal transplants performed at our institution between May 1, 2010, and February 28, 2015. All patients undergoing renal transplant, either living or deceased donor, were evaluated for belatacept treatment. Those who were Epstein-Barr virus (EBV) seronegative or human immunodeficiency virus (HIV) positive; had a history of posttransplant lymphoproliferative disease, lymphoma, or other hematologic malignancy; were undergoing treatment for latent tuberculosis; or were the recipient of a simultaneous extrarenal organ were excluded.
For the first part of the review period-May 1, 2010, to July 2011-a tacrolimus-based immunosuppression regimen was the standard of care at our center. Overall, 229 patients underwent renal transplant during this period, of which 205 received the standard tacrolimus regimen. These 205 patients were used as the tacrolimus control/comparator group for this retrospective study (Figure 1) . The remaining 24 patients were enrolled in clinical trials.
Following approval of belatacept by the U.S. Food and Drug Administration (FDA) in June 2011, we transitioned our standard-of-care immunosuppression regimen from a tacrolimus-to belatacept-based regimen. From July 2011 to February 28, 2015, an additional 728 patients received a kidney transplant alone at our center. Of those, 540 (74%) patients received a belatacept-based immunosuppression regimen. There were various reasons why the other 188 patients did not receive belatacept treatment during this time, including that 118 of 188 were enrolled in a clinical trial using a different immunosuppression regimen; 25 of 188 were EBV seronegative, precluding belatacept use per label; 14 of 188 patients were HIV positive; and 31 of 188 patients were in the other category, which included history of hematologic malignancy, language barriers, and transportation or distance issues that would potentially include difficulties in returning to the transplant center for infusions long-term. This retrospective review was approved by the institutional review board at Emory University (no. 00059283).
Immunosuppression and treatment regimens
The standard tacrolimus-based regimen (Tac) also included anti-IL-2R induction (basiliximab 20 mg intravenously [IV] on days 0 and 3 or 4), mycophenolate mofetil (MMF; 1 g twice daily), and a short steroid taper (methylprednisolone 500 mg IV intraoperatively, 250 mg IV on day 1, 125 mg IV on day 2, and prednisone 5 mg on day 3 and daily thereafter). The initial belatacept regimen (Bela; Figure 1 ) followed the package insert including intravenous infusion of belatacept (10 mg/kg) during surgery and on posttransplant days 4, 14, 28, 56, and 84, with subsequent doses (5 mg/kg) given every 4 weeks thereafter. Patients also received basiliximab induction, MMF, and steroid, as described above in the standard tacrolimus control regimen (except for Bela B : 20 mg days 3-28, 15 mg days 29-35, 10 mg days 36-42, 5 mg daily thereafter). Details of the combined belatacept/tacrolimus regimens are shown in Figures 1 and 2 and are similar to a regimen that has been reported previously (14) . In short, patients receiving the Bela/Tac Short regimen were treated with a modified belatacept regimen that eliminated doses at days 4 and 14. They also received tacrolimus twice daily to achieve trough doses 8-12 ng/mL from the day of transplant through the first 3 mo and then tapered over the next 2 mo to end by 5 mo after transplant. Patients receiving Bela/Tac Long regimens were treated with the same modified belatacept dosing regimen described above and received tacrolimus twice daily for the first 9 mo after transplant and then tapered to end dosing after month 11 after transplant. The Bela/Tac Long(A) trough level targeted months 0-3 (8-12 ng/mL), months 4-6 (5-8 ng/mL), and months 7-9 (3-5 ng/mL), and then tapered months 10-11. Bela/Tac Long(B) targeted months 0-1 (8-12 ng/mL), months 2-6 (5-8 ng/mL), and months 7-9 (3-5 ng/mL), and then tapered months 10-11.
All patients received Pneumocystispneumonia prophylaxis with daily bactrim or equivalent. Cytomegalovirus (CMV) prophylaxis was determined based on the serologic status of the donor and the recipient. All patients who were CMV IgG positive (IgG + ) prior to transplant were treated with valganciclovir daily for 3 mo with dosing adjusted for renal function (estimated GFR [eGFR] >60, 450 mg daily). Patients who were CMV IgG negative (IgG À ) and received a kidney from a CMV IgG + donor were considered high risk for CMV infection and were treated with valganciclovir daily for 6 mo with dosing adjusted for renal function (eGFR >60, 900 mg daily). All patients who were CMV IgG + prior to transplant were tested monthly for evidence of CMV viremia using standard polymerase chain reaction (PCR) laboratory tests until month 12. In addition, all patients had BK PCR tested monthly through the first year after transplant.
Treatment for biopsy-proven rejection was according to Banff grade. Borderline and grade 1A were treated with corticosteroid pulse. All rejections of grade IB or higher were treated with thymoglobulin (1.5 mg/kg IV daily: grades IB and IIA, 7 days; grade IIB, 10 days; grade III, 14 days) and a 6-week steroid taper.
Outcomes and statistical analyses
Kaplan-Meier curves were generated for freedom from rejection, development of donor-specific antibody, and patient and graft survival. A log-rank Figure 1 : Treatment groups. Description of the various belatacept-based immunosuppression regimens. Reasons for discontinuation of belatacept therapy and assessment of follow-up are included. The final boxes in each column represent the number of patients who remained on treatment and were available for analysis at the latest time point for each group. These numbers include those who experienced graft loss or death but whose data were included in the analysis with imputation.
test was used to assess statistical significance. Graft loss was defined as return to dialysis for >2 weeks. For calculations of freedom from graft loss, both graft loss and death were considered as an event, whichever came first. Rejection was defined as biopsy-proven rejection of grade IA or greater, as determined by a staff pathologist using standard Banff criteria (15) . For calculations of freedom from rejection, patients who died were censored at the time of their death. A v 2 analysis was used to determine significance between the treatment groups for histologic grade of rejection, incidence of viremia, and incidence as well as cause for conversion. For freedom from development of donor-specific antibody, the data were censored at either patient death or conversion from belatacept treatment. The eGFR was calculated using the MDRD equation at defined time points after transplant. Mean eGFR values at these time points were compared between treatment regimens, and statistical significance was determined by t-test.
To examine the effect of treatment on eGFR values longitudinally over time, a repeated measures model was constructed. Initial models treated time as a categorical variable, and an unstructured covariance matrix was used. When the model did not converge, either a compound symmetry or Toeplitz matrix were used. In these analyses, eGFR values from patients who experienced graft loss or death were imputed as zeros after the event. These models were labeled as "intent to treat, imputed." In the "on treatment" analyses, patients who transitioned off of belatacept were censored from the analysis at the time they stopped belatacept therapy. Patients who experienced death or graft loss prior to cessation of belatacept therapy were included in the analyses, and subsequent time points after death or graft loss were imputed as zeros. A repeated measures model in which patients with death and graft loss were censored at the time of the event without imputation of the missing values was also generated. Last, a slope-based model with imputation of missing values was also used to determine whether there was a difference between the slope for the belatacept-and tacrolimus-based treatment regimens, for which linearity of the eGFR values between months 1 and 48 was assumed. Time was regarded as a continuous variable, treatment as a fixed effect, and intercept and time as random effects; no adjustment was made for other potentially confounding variables. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Results
CNI-free, belatacept-based immunosuppression is associated with high rates of rejection early after renal transplantation Following FDA approval of belatacept in June 2011, we implemented a costimulation blockade-based standard-ofcare immunosuppressive regimen using belatacept at our center. All patients undergoing renal transplant, either living or deceased donor, were evaluated for belatacept treatment. The initial belatacept-based standard-of-care regimen included anti-IL-2R induction, MMF, a short steroid taper, and belatacept consistent with the original package insert. In total, 97 patients received this belatacept treatment regimen and were followed to assess posttransplant outcomes. Outcomes from all belatacept treatment groups were compared in a retrospective fashion with a historical cohort of renal transplant recipients who received a similar treatment regimen except that tacrolimus was used as the primary immunosuppressant instead of belatacept. These patients (n = 205) underwent transplantation at our center in the 15 mo preceding belatacept approval. The details of the belatacept dosing, tacrolimus trough target levels, and concomitant immunosuppression for all treatment regimens are detailed in Figures 1 and 2 . Baseline transplant and demographic characteristics were similar for all groups (Table 1) .
Compared with tacrolimus-treated patients, there was a significantly increased rate of biopsy-proven acute cellular rejection in patients treated with the belatacept regimen (1-year rejection, Bela vs. Tac, 50.5% vs. 20.5%; Figure 3A) . This increased acute rejection rate did not improve with an increase in the steroid taper from 5 mg on day 3 to 20 mg for the first month and then tapered to 5 mg by 6 weeks (Bela B data not shown). In addition the grades of rejection were more severe in the belatacepttreated patients ( Figure 3B ). Despite the higher rates and grades of rejection, the overall rates of patient and graft survival at 4 years were not different (Tac vs. Bela, 4-year patient rate: 90.2% vs. 91.8%, p = 0.73; 4-year graft rate; 85.4% vs. 89.7%, p = 0.46) ( Figures 4A and B) .
Use of short-course tacrolimus prevents early rejection seen with belatacept-based immunosuppression Given the high rates of rejection associated with our initial belatacept regimen, we altered the regimen to include the use of a short course of tacrolimus in the early posttransplant period in combination with a modified belatacept dosing regimen (Bela/Tac short ) (Figures 1 and 2 ). Doses of belatacept initially given on days 4 and 14 were eliminated while tacrolimus target trough levels were kept similar to our standard tacrolimus regimen for the first 3 mo after discharge (8-12 ng/mL). Similar to depleting antibody-based induction therapies that have immunomodulatory effects for several months after administration, all patients received tacrolimus induction for 3 mo at therapeutic target trough levels, after which it was tapered over a 2-mo period with the goal of discontinuation by the end of the fifth month after transplant.
Initial rejection rates were similar to the historical tacrolimus-treated cohort and superior to the initial belatacept treated group (3-mo rejection rates: Tac 17.1% vs. Bela/Tac short 14.9%; Bela/Tac short 14.9% vs. Bela 38.2%) ( Figure 3C ). After tapering of the tacrolimus therapy, however, an additional cohort of patients experienced rejection (12-mo rejection rates: Tac 20.5% vs. Bela/Tac short 33.3%; Bela/Tac short 33.3% vs. Bela 50.5%) ( Figure 3C ). As in the initial protocol, these rejections tended to be of a higher histologic grade ( Figure 3D ). Again, despite the increased rates and grades of rejection, the overall patient and graft survival at 3 years remained comparable between treatment groups (Tac vs. Bela/Tac short , 3-year patient rate: 93.7% vs. 92%, p = 0.99; 3-year graft rate: 87.8% vs. 90.8%) ( Figures 4C and D) .
It has long been recognized that the risk of acute rejection diminishes with time after transplant. Given that rates of rejection were still unacceptable when tacrolimus was tapered off between 3 and 5 mo, we reasoned that a longer duration of tacrolimus therapy might avoid the higher rate of rejection observed with belatacept therapy. This hypothesis was supported by the phase II conversion study in which patients transitioned from CNI therapy to belatacept with low rates of rejection as early as 6 mo after transplant (16). Accordingly we modified the protocol to provide extended tacrolimus exposure (Bela/Tac extendedA ) (see Figures 1 and 2 ). Tacrolimus trough level targets were 8-12 ng/mL for the first 3 mo, 5-8 ng/mL for months 4-6, and 3-5 ng/mL for months 7-9. Patients were then tapered off of tacrolimus over the next 2 mo with a goal of discontinuation by the end of month 11.
Rates of acute rejection in patients receiving extended tacrolimus induction were similar to our tacrolimustreated cohort and significantly better than either the belatacept regimen or the belatacept regimen with the short tacrolimus induction. Histologic grades of rejection were similar between the Tac and Bela/Tac extendedA groups. Given that the goal was to limit CNI exposure and possibly reduce donor-specific antibody (DSA) formation to improve long-term allograft function, we reasoned that the length of tacrolimus induction was more important than achieving higher trough levels to avoid early rejection. We next modified the extended tacrolimus induction regimen to include more rapid reduction in goal trough levels of 8-12 ng/mL for only the first month, 5-8 ng/mL for months 2-6, and 3-5 ng/mL for months 7-9, with planned discontinuation by month 11 (Bela/ Tac extendedB ) (Figure 2 ). For analysis purposes, the two Bela/Tac extended treatment groups were combined. Patients treated with the Bela/Tac extended regimens experienced similar rates and grades of acute rejection compared with the Tac cohort and significantly less rejection than either the Bela or Bela/Tac short cohorts (12-mo rejection rates: Bela/Tac extended 16% vs. Tac Regimens are defined in Figure 1 . DCD, donation after circulatory death; ECD, extended criteria donor; ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; PCKD, polycystic kidney disease; PD, Pediatric donation en bloc; PRA, panel reactive antibody; SCD, standard criteria donor. 20.5%; Bela/Tac extended 16% vs. Bela/Tac short 33.3%; Bela/Tac extended 16% vs. Bela 50.5%) (Figure 3 ).
Improved renal function with belatacept-based therapy
One of the primary benefits identified in the clinical trials of belatacept was an improvement in renal function. Recent reporting of the 7-year follow-up confirmed a stable to increased GFR in belatacept-treated patients versus worsening renal function over time in the group treated with cyclosporine (%70 vs. 45 mL/min at 7 years) (13). All patients were followed for renal function and other factors per our standard of care protocol. The eGFR were calculated using the MDRD equation at defined time points after transplant in a retrospective fashion. Those patients who experienced death or graft loss during the follow-up period continued to be included in an intent-to-treat analysis. For this analysis, eGFR values were imputed as zero from the time of the event ( Figures 5A-D) . In addition, a repeated measures model was generated to compare mean eGFR values between treatment groups. Time was held as a categorical variable, and results were generated and analyzed with and without imputation of values of patients who experienced death and graft loss (Figures S1A-D and S2A-D).
Similar to the published clinical trial experience, patients treated with any of the belatatcept-based regimens had significantly higher eGFR values than those patients treated with tacrolimus ( Figures 5, S1 and S2). This improvement in renal function was accentuated when patients who stopped belatacept therapy for various reasons were censored from the analysis at the time of their discontinuation, labeled "on-treatment" analysis (Figures 5E-H, S1E-H, and S2E-H). When all belatacepttreated patients who remained on therapy were compared with those who received only tacrolimus-based immunosuppression, there was a significant difference in renal function at 4 years after transplant ( Figure 5H ) (all Bela 63.8 mL/min vs. Tac 46.2 mL/min, p < 0.0001). Consistent with the phase III study results (17) , when the slope of the combined cohort was analyzed using a repeated measures model with time held as a continuous variable, there was a slight uptrend in eGFR over time in the belatacept-treated patients in contrast to the negative slope, indicating loss of renal function over time, in those treated with tacrolimus alone (all Bela +2.62 mL/min per year vs. Tac À1.60 mL/min per year, p < 0.0001).
Rates of CMV and BK viremia were similar between groups With the development of a new immunosuppressant, there is always the desire to strike the right balance between providing sufficient immunosuppressive activity to prevent rejection while avoiding overimmunosuppression, which could result in problems with protective immunity. As a strategy to assess the overall level of immunosuppression in our belatacept-based immunosuppressive regimen, we evaluated the rates and severity of both CMV and BK viremia during the first year after transplant. In an attempt to quantify the significance of viremia for both CMV (IU copies/ml) and BK (copies/ml), we stratified the result based on a cutoff of 10 000.
there were no significant differences in the rates of either CMV or BK viremia when we compared belatacept-and tacrolimus-based treatments ( Figures 6A  and B) . When we examined the belatacept treatment groups individually, we did find that there was a significantly higher rate of detectable CMV viremia in the initial belatacept treatment regimen, which did not include any adjunct tacrolimus ( Figure 6B ) (Bela 27.8% vs. Tac 14.2% p = 0.02). This is likely due to the significantly higher rate of rejection in that group and the subsequent administration of thymoglobulin and steroid used to treat those rejection episodes rather than the result of the initial immunosuppression regimen itself, which included the least immunosuppression of all belatacept treatment groups. BK nephropathy was a rare event with no significant differences between treatment groups. In addition, there were no differences in serious infections requiring hospital admission (data not shown).
The majority of patients achieved CNI-free immunosuppression using a belatacept-based regimen Not all patients who were initially treated with a belatacept-containing regimen remained on therapy. By protocol, any patient who developed a grade III rejection or had recurrent focal segmental glomerulosclerosis (FSGS) was transitioned off of belatacept therapy and maintained with tacrolimus as the principal immunosuppressant. Most patients continued to receive belatacept as their primary immunosuppressant (Figure 7 ). In the belatacept and Bela/Tac short regimens, there were patients who were transitioned back to tacrolimus following episodes of rejection (10.3% and 6.9%, respectively) ( Table 2 ). In the Bela/Tac extended cohort, the rate of acute rejection was significantly less ( Figures 3E and F) , as was the conversion rate for rejection (Table 2 ) (Bela 10.3% vs. Bela extended 1.4%, p < 0.0001; Bela short 6.9% vs. Bela extended 1.4%, p = 0.003). Additional reasons for conversion off of belatacept included issues related to intravenous infusion or poor intravenous access, patient preference, distance from an infusion center, infection or persistent viremia, or recurrent FSGS. The overall rate of conversion appeared to decrease with protocol optimization (Figure 7 ) (Bela 23%, Bela/Tac short 21%, Bela/Tac extended 17%).
Belatacept-based regimens are associated with lower rates of DSA formation and improved long-term outcomes In addition to the significant improvement in renal allograft function reported in the 7-year data from the BENE-FIT trial, patients treated with belatacept had a significantly lower risk of DSA formation: %18% in the cyclosporine treated patients versus %2-4% in those receiving belatacept (13) . Given the association between the development of DSA and inferior long-term allograft function, we evaluated the rates of DSA formation in our patients. Despite the significantly higher rates and grades of rejection seen in the Bela and Bela/Tac short cohorts, the rate of DSA formation in those patients treated with belatacept was significantly lower compared with those receiving a standard tacrolimus-based regimen (Figure 8 ) (Tac 8.82% vs. all Bela 4.14% at 1 year, p = 0.04).
The goal of renal transplantation is the long-term survival of both the patient and the transplanted kidney. To evaluate the impact of belatacept treatment on long-term patient and graft function, we assessed the number of patients who were alive with a functioning graft and an eGFR >30. Those patients who experienced death or graft loss had eGFR values imputed as zero after the event. In an intent to treat analysis, patients treated with belatacept-based immunosuppression were less likely to have a sustained eGFR <30 compared with the cohort treated with tacrolimus, although this did not reach statistical significance (4-year Tac 19.5% vs. all Bela 13.3%, p = 0.40) ( Figure 9A ). There was, however, a statistically significant difference when those patients who had stopped belatacept therapy were censored from the analysis reflecting the benefit of avoiding CNI treatment (4 years: Tac 19.5% vs. Bela 7.6%, p = 0.0003) ( Figure 9B ), similar to the phase III clinical trial results and suggesting a potential impact on long-term graft function/survival (17) .
Discussion
In 2011, after completion of a multiyear international clinical development program, belatacept was approved as A B Figure 6 : Cytomegalovirus (CMV) and BK viremia. Percentage of cohort that developed detectable BK virus (A) or CMV (B) viremia. Positive patients were stratified by highest level of viremia recorded within the first year after transplant: <10 000 (low positive) or >10 000 copies/mL. Those patients who were not tested were presumed to be negative. Regimens are defined in Figure 1 . an alternative to CNIs in renal transplantation. Based on the high utilization of tacrolimus in the 2015 Organ Procurement and Transplantation Network annual report, there is evidence that use of belatacept in clinical practice is comparatively low. There have been few reports of outcomes observed with belatacept in diverse recipient populations as opposed to selected groups that are eligible for and choose to participate in clinical trials. In this retrospective analysis, we have reported on our experience with 540 recipients treated with belataceptbased regimens as standard of care and the outcomes of a historical comparator group that received a tacrolimusbased regimen. There were a number of key observations. First, rates of short-term patient and graft survival were comparable for all groups. Second, there was a significantly higher rate of rejection with belatacept regimens that modeled the regimens in the BENEFIT trial. When a 3-mo course of tacrolimus was combined with belatacept, the rejection rate was significantly reduced, although not to the same level previously seen with standard tacrolimus-based therapy. Only when the tacrolimus taper was extended to 9 mo was the rejection controlled to a level comparable to that seen with standard tacrolimus dosing. The majority of belatacept-treated patients were able to transition to a CNI-free regimen by 1 year after transplant. In addition, we found that the rates and levels of BK and CMV viremia were similar across regimens. Maybe most important, we found that the rates of de novo DSA formation were significantly lower in the groups treated with belatacept-a finding consistent with the published clinical trials-and that eGFR was superior in belatacept-treated patients compared with those on the tacrolimus-based maintenance regimen (15 mL/min at 4 years).
An important finding from our experience was the significantly increased rate of acute rejection seen when we used belatacept in a regimen similar to that reported in the BENEFIT trial. Based on the results from the clinical trial, higher rates and grades of rejection with belatacept treatment were not unexpected; however, the frequency and severity of rejection in our initial cohort was significant. Several factors may have contributed to the observed increase in rejection. First, the BENEFIT trial population was considerably different from our patient population. The percentage of patients who had received a previous transplant, those with higher panel reactive antibody, the degree of HLA mismatches, and the percentage of black recipients were all significantly higher in our cohort. In addition, the steroid regimen utilized in the BENEFIT trial was not explicitly prescribed. A post hoc analysis of steroid dosing in the trial showed that patients received significantly higher doses of steroid for a longer period of time after transplant in contrast to our regimen, in which the steroid dosing more closely approximated contemporary practice (mean dose of prednisone at discharge, 1 and 3 mo after transplant When faced with the higher rates and grades of rejection in the initial belatacept treatment regimen, there were several options for optimization including the use of T cell depletion for induction. Previous reports utilizing belatacept in steroid-avoidance regimens have had mixed results. An early trial assessing the combination of belatacept, thymoglobulin induction, and either MMF or sirolimus in primary renal transplant recipients suggested a higher rate of rejection in patients treated with belatacept/MMF compared with belatacept/sirolimus or a tacrolimus-based control regimen, although this was not statistically significant, given the small sample size (18) . The combination of alemtuzumab, belatacept, and sirolimus has been used successfully in a selected cohort to achieve low rejection rates and excellent graft function, with many patients eventually weaning to belatacept monotherapy (19) . A more recent study supported by the National Institutes of Health clinical trials in organ transplantation (CTOT-16) and evaluating the combination of thymoglobulin, belatacept, and MMF in a steroidavoidance regimen was halted because of lack of efficacy, specifically, unacceptably high rejection rates (20) .
Our choice to use an adjunct extended period of tacrolimus induction to control the early posttransplant rejection seen with belatacept allows for the ability to titrate the level of immunosuppression if necessary by modifying tacrolimus target levels depending on the individual circumstance. This strategy stands in contrast to traditional depletional therapy, for which, once given, one is unable to alter immunosuppressive effects for the next several months. The current clinical trial evaluating the use of thymoglobulin, belatacept, and everolimus will provide additional insight into the efficacy of the combination of T cell depletion and belatacept in a larger study population (ClinicalTrials.gov identifier NCT02137239).
The observation that later weaning of tacrolimus facilitates a significantly lower rate of rejection when patients transition to a CNI-free regimen defines an early period of immunologic instability in which a subset of patients will experience costimulation blockade-independent rejection. Current research efforts by our group and others seek to define potential immunologic parameters that might identify those patients at risk of rejection when treated with belatacept (21, 22) . Accurate identification of those patients who are at low risk of rejection may permit us to stratify them to avoid adjunct tacrolimus treatment and to determine the optimal timing of the transition off of tacrolimus therapy for others.
Perhaps the most meaningful data included in this report related to the inclusion of our tacrolimus-treated cohort with long-term evaluation of both renal function and rates of DSA. Although this analysis is retrospective and carries with it all the inherent caveats associated with that type of analysis, it is nonetheless informative. In a diverse group of renal transplant recipients that mirrors the patient population served by many transplant centers, we report a steady decline in renal function over time with tacrolimus treatment. These data are consistent with the observed association of long-term tacrolimus exposure on renal function. In contrast, treatment with belatacept-containing regimens is associated with maintenance or even improvement in renal function following transplantation. Our data confirm the recently published report detailing the 7-year results of the BENE-FIT trial including sustained improvements in renal function over time. Despite transient tacrolimus exposure early after transplant, our patients also experienced a significant benefit in renal function compared with patients treated with tacrolimus. The 7-year data also demonstrated a benefit in the combined end point of patient and graft survival. When we examined the probability of patient survival with an eGFR >30, there was a significant benefit for those patients treated with and maintained on belatacept therapy. This is congruent with the 7-year data from both the BENEFIT trial, showing a 43% risk reduction in patient and graft survival, and the BENE-FIT-EXT analysis, showing significant improvement for a similar combined end point (13) . Our most recent protocol modification includes lower tacrolimus target trough levels from the time of transplant (5-8 ng/mL in months 0-6, 3-5 ng/mL in months 7-9, and then tapered off over months 9-11) with rates of acute rejection comparable to our previous regimen (Bela/Tac extendedC , data not shown). Ideally, less exposure to tacrolimus earlier should minimize any negative impact on renal function.
The development of DSA is an increasingly recognized risk factor for late allograft failure (23) (24) (25) . We report that treatment with belatacept therapy significantly reduces DSA formation compared with tacrolimus-based immunosuppression. Even with the high rates of acute cellular rejection observed in the first belatacept cohort, DSA formation was low. This confirms the finding seen in the recent long-term follow-up report of the BENEFIT trial in which %18% of the cyclosporine-treated patients developed DSA compared with 2-4% of the patients receiving belatacept. This is consistent with the substantial experimental evidence that supports the efficacy of belatacept preventing DSA formation (10, 26) . DSA formation was significantly reduced within the first year after transplant, supporting the initiation of belatacept at the time of transplant instead of waiting to convert later. In addition to the potential biological benefit in DSA reduction with initial belatacept therapy, there is also the practical consideration of the potential difficulty of convincing patients to change to an intravenous infusion at a later time point, after they are already accustomed to only oral medications, versus starting from the time of transplant on a regimen that includes monthly infusions.
The goal of kidney transplantation is to extend and improve the lives of patients with end-stage renal disease. Although many strategies exist to improve long-term outcomes, an approach with increasing support is the use of immunosuppressive agents, such as belatacept, to avoid the deleterious effects of current immunosuppressants that negatively influence longterm patient and graft survival. We developed a nondepletional, costimulation blockade-based immunosuppression regimen that achieves patient and graft survival equivalent to a tacrolimus-based regimen. This regimen achieved acceptable rates of acute rejection and promoted improved renal function, providing a viable strategy for long-term CNI-free immunosuppression in contemporary clinical practice. The long-term benefits of improved renal function and presumably lower cardiovascular risk should translate into increases in patient and graft survival.
Supporting Information
Additional Supporting Information may be found in the online version of this article. 
